These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10428503)

  • 41. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
    Vera J; Savoldo B; Vigouroux S; Biagi E; Pule M; Rossig C; Wu J; Heslop HE; Rooney CM; Brenner MK; Dotti G
    Blood; 2006 Dec; 108(12):3890-7. PubMed ID: 16926291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
    Wooldridge JE; Dahle CE; Weiner GJ
    Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
    Oshimi K; Seto T; Oshimi Y; Masuda M; Okumura K; Mizoguchi H
    Blood; 1991 Mar; 77(5):1044-9. PubMed ID: 1825287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.
    Takeuchi T; Barcos MP; Seon BK
    Cancer Res; 1991 Jun; 51(11):2985-93. PubMed ID: 1709587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
    Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
    Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
    Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.
    Stel AJ; Kroesen BJ; Jacobs S; Groen H; de Leij LF; Kluin-Nelemans HC; Withoff S
    J Immunol; 2004 Nov; 173(10):6009-16. PubMed ID: 15528335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
    Möller SA; Reisfeld RA
    Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific recognition of human leukemic cells by allogeneic T cell lines.
    Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
    Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential activation through the TCR-CD3 complex affects the requirement for costimulation of human T cells.
    Kawaguchi M; Eckels DD
    Hum Immunol; 1995 Jun; 43(2):136-48. PubMed ID: 7591873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
    Scrivener S; Goddard RV; Kaminski ER; Prentice AG
    Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
    Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A
    Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.